Signs of angels come at the most unexpected — yet vital — moments in our lives, columnist Juliet Taylor writes.

The analyses offer evidence for a slowing of functional decline and improved survival outcomes with long-term Radicava ORS by ...

Neither memantine nor trazodone was able to slow amyotrophic lateral sclerosis (ALS) disease progression in a platform ...

A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...

RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...